Brought to you by 
Inhale, 3-D Pharmaceuticals develop blood platelet drug
Mar 2002
Executive Summary
3-Dimensional Pharmaceuticals (small-molecule drug discovery and development) has licensed Inhale's Shearwater subsidiary's PEGylation technology (acquired when Inhale bought the subsidiary last year) to further develop 3DP-3534, a PEGylated peptide in preclinical development to prevent and treat thrombocytopenia (low blood platelet count).
Deal Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Intra-Biotech Deal
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Inhale, 3-D Pharmaceuticals develop blood platelet drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice